Lisa R Forbes1, Josh Milner, Elie Haddad. 1. aSection of Immunology, Department of Pediatrics, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital Center for Human Immunobiology, Houston, Texas bNational Institutes of Health, Genetics and Pathogenesis of Allergy Section, Laboratory of Allergic Diseases, NIAID, Bethesda, Maryland, USA cDepartment of Pediatrics and Department of Microbiology, Immunology and Infectiology, University of Montreal, CHU Sainte-Justine Research Centre, Montreal, Quebec, Canada *Josh Milner and Elie Haddad share the senior authorship to the writing of this article.
Abstract
PURPOSE OF REVIEW: Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor involved in a wide variety of cellular functions. Germline loss-of-function mutations are known to cause hyper-IgE immunodeficiency (autosomal dominant hyper IgE syndrome), whereas somatic gain-of-function mutations have been described in large granular cell leukemia, and polymorphisms in STAT3 have been associated with inflammatory bowel disease and other solid organ tumors. The review examines recent discoveries in our understanding of the nonmalignant disease processes affected by STAT3 mutations in human disease. RECENT FINDINGS: Germline STAT3 gain-of-function mutations have recently been identified in patients with an early-onset autoimmunity/lymphoproliferative syndrome. STAT3 plays a previously unrecognized role in several facets of the pathogenesis of allergy. Loss-of-function STAT3 mutations revealed critical roles for STAT3 in the development and function of several lymphocyte populations and in their role in host defense. SUMMARY: The discovery of new gain-of-function mutations in STAT3, as well as new studies among patients with loss-of-function mutations, expand the understanding of the pathophysiology of STAT3 function and its importance in regulating the immune system. These findings contribute to elucidating STAT3 biology and clinical symptoms in patients with the different disease phenotypes.
PURPOSE OF REVIEW: Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor involved in a wide variety of cellular functions. Germline loss-of-function mutations are known to cause hyper-IgE immunodeficiency (autosomal dominant hyper IgE syndrome), whereas somatic gain-of-function mutations have been described in large granular cell leukemia, and polymorphisms in STAT3 have been associated with inflammatory bowel disease and other solid organ tumors. The review examines recent discoveries in our understanding of the nonmalignant disease processes affected by STAT3 mutations in human disease. RECENT FINDINGS: Germline STAT3 gain-of-function mutations have recently been identified in patients with an early-onset autoimmunity/lymphoproliferative syndrome. STAT3 plays a previously unrecognized role in several facets of the pathogenesis of allergy. Loss-of-function STAT3 mutations revealed critical roles for STAT3 in the development and function of several lymphocyte populations and in their role in host defense. SUMMARY: The discovery of new gain-of-function mutations in STAT3, as well as new studies among patients with loss-of-function mutations, expand the understanding of the pathophysiology of STAT3 function and its importance in regulating the immune system. These findings contribute to elucidating STAT3 biology and clinical symptoms in patients with the different disease phenotypes.
Authors: K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205
Authors: Andrea M Siegel; Jennifer Heimall; Alexandra F Freeman; Amy P Hsu; Erica Brittain; Jason M Brenchley; Daniel C Douek; Gary H Fahle; Jeffrey I Cohen; Steven M Holland; Joshua D Milner Journal: Immunity Date: 2011-11-23 Impact factor: 31.745
Authors: Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake Journal: J Immunol Date: 2007-10-01 Impact factor: 5.422
Authors: Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2013-11-01 Impact factor: 10.793
Authors: Sarah E Flanagan; Emma Haapaniemi; Mark A Russell; Richard Caswell; Hana Lango Allen; Elisa De Franco; Timothy J McDonald; Hanna Rajala; Anita Ramelius; John Barton; Kaarina Heiskanen; Tarja Heiskanen-Kosma; Merja Kajosaari; Nuala P Murphy; Tatjana Milenkovic; Mikko Seppänen; Åke Lernmark; Satu Mustjoki; Timo Otonkoski; Juha Kere; Noel G Morgan; Sian Ellard; Andrew T Hattersley Journal: Nat Genet Date: 2014-07-20 Impact factor: 38.330
Authors: Lia Furlaneto Marega; Janine Schincariol Sabino; Marcus Vinicius Pedroni; Marcelo Teocchi; Carolina Lanaro; Dulcinéia Martins de Albuquerque; Irene Pereira Dos Santos; Fernando Ferreira Costa; Maria Marluce Dos Santos Vilela Journal: Immunol Res Date: 2021-08-14 Impact factor: 2.829
Authors: Koshi Yamada; Zhi-Qiang Huang; Milan Raska; Colin Reily; Joshua C Anderson; Hitoshi Suzuki; Hiroyuki Ueda; Zina Moldoveanu; Krzysztof Kiryluk; Yusuke Suzuki; Robert J Wyatt; Yasuhiko Tomino; Ali G Gharavi; Amy Weinmann; Bruce A Julian; Christopher D Willey; Jan Novak Journal: Kidney Int Rep Date: 2017-07-19